Latest news with #dryeye
Associated Press
7 hours ago
- Business
- Associated Press
Leading New York Ophthalmologist Integrates Tixel® into Dry Eye Treatments
WATERTOWN, N.Y., June 3, 2025 /PRNewswire/ -- Dr. Noaman Sanni, a leading ophthalmologist and CEO of Center for Sight New York, has witnessed significant patient and revenue growth after adding Tixel i into his practice. Tixel i, Novoxel's FDA-cleared device, utilizes patented Thermo-Mechanical Action® (TMA) to effectively treat Meibomian Gland Dysfunction (MGD) – a common cause of dry eye – in under two minutes. Within just two months, Dr. Sanni's team treated over 225 patients, making Tixel i a truly transformative addition to their dry eye protocols. Dr. Sanni noted, 'We were not really focused on the business aspect, because we were focusing on the medical aspect and helping our patients. Therefore, I was surprised at the positive financial impact due to rapid patient acceptance.' CLINICALLY PROVEN RESULTS - Tixel i isn't just praised by patients; it's backed by strong clinical data. A pivotal trial showed remarkable improvements: PHYSICIAN ENDORSEMENT - Dr. Debra Koloms, Medical Director at Center for Sight New York, personally experienced Tixel i treatment for her own dry eye. 'After 2 Tixel i treatments, I no longer need punctal plugs or drops,' she shared. After personally treating over 50 patients in six weeks, Dr. Koloms declared, 'In 40 years of practice, this is the most impressive treatment I've ever seen for Meibomian Gland Dysfunction.' Center for Sight New York offers consultations and Tixel i treatment previews for those interested in learning more about this innovative dry eye solution. Novoxel, Tixel, Thermo-Mechanical Action, and TMA are registered trademarks of Novoxel LTD. ABOUT NOVOXEL Established in 2011, Novoxel Ltd. focuses on scientific and clinical innovation, holding numerous patents worldwide. Their Tixel family of products utilize proprietary Thermo-Mechanical Action (TMA®) to deliver noticeable clinical results. These treatments are non-invasive, radiation-free, require minimal downtime, and involve no expensive single-use cartridges, bleeding, or significant pain. To learn more, visit ABOUT CENTER FOR SIGHT Established in the 1940s, Center for Sight New York is one of Northern New York's largest and most respected eye care practices, with locations in Watertown and Ogdensburg. Under the leadership of Dr. Noaman Sanni since 1995, the practice boasts a team of board-certified ophthalmologists and skilled technicians. They provide state-of-the-art diagnostics and advanced treatments with a patient-centered approach, aiming to improve quality of life through exceptional vision solutions. View original content to download multimedia: SOURCE Novoxel Inc.
Yahoo
3 days ago
- Business
- Yahoo
Novoxel Inc. and GPOphtho Finalize Strategic Agreement to Deliver Breakthrough Dry Eye Treatments and Aesthetic Procedures to Eyecare Physicians Nationwide
KNOXVILLE, Tenn., May 31, 2025 /PRNewswire/ -- Novoxel Inc. and GPOphtho announce their agreement to expand access to Novoxel's innovative Tixel® device family across the United States. This collaboration aims to deliver breakthrough dry eye treatments and aesthetic procedures to eyecare physicians nationwide. Expanding Access to Advanced Dry Eye and Aesthetic Solutions The agreement grants GPOphtho's network of ophthalmologists and optometrists discounted pricing and value-added packages for Novoxel's Tixel devices. Tixel i® is specifically designed to treat Meibomian Gland Dysfunction (MGD), offering a fast and targeted solution for both upper and lower eyelids. A recent clinical trial (Sanni, et al, 2025) concluded that Tixel i is a safe, non-pharmacologic, first-line treatment for MGD. "What sets Tixel i apart from other dry eye treatments is that it only takes 2 minutes for both eyes to be treated. Unlike older technology, Tixel i safely treats upper and lower eyelids to maximize improvement," says Cynthia Matossian, MD, FACS, and CEO of GPOphtho. The FDA-cleared family of products provide year-round treatments for all skin types and age groups. They offer non-invasive rejuvenation without needles, bleeding, or pain, minimal downtime, no expensive consumables, and are radiation-free. Empowering Eyecare Physicians with New Revenue Streams "Eyecare physicians are uniquely positioned to incorporate aesthetic procedures into their practices due to their expertise in the periocular anatomy and their familiarity with ophthalmic laser technology," says Cynthia Matossian, MD, FACS, and CEO of GPOphtho. This agreement will enable eyecare professionals to easily integrate both functional and cosmetic procedures, creating new revenue streams and enhancing patient satisfaction. Both Novoxel and GPOphtho are committed to bringing innovative, cutting-edge technology to more patients and practices across the US. For product demos or pricing information, visit Existing GPOphtho members can inquire about adding Tixel through their GPOphtho contact. ABOUT NOVOXELEstablished in 2011, Novoxel Ltd. focuses on scientific and clinical innovation. Novoxel has been granted numerous patents around the world. The company's Tixel family of products use proprietary Thermo-Mechanical Action (TMA®) to deliver noticeable clinical results even though treatments are non-invasive. There is minimal downtime, no expensive single-use cartridges, no bleeding, and minimal/no pain. Because the affordable treatments are radiation-free, safety eyewear is not required for clinicians. Visit for more information. ABOUT GPOPHTHOGPOphtho's mission is to save our members time and money for all of their business needs by becoming the most comprehensive ophthalmic group purchasing organization. By leveraging collective buying power, GPOphtho is able to negotiate discounted rates and value-added packages for a diverse range of products and services, allowing physicians and their staff to focus on providing the best care for their patients. Plus, members can take advantage of all GPOphtho's negotiated contracts without paying administrative fees. For more information, visit Interested eyecare physicians can join GPOphtho at no cost. View original content to download multimedia: SOURCE Novoxel Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Novoxel Inc. and GPOphtho Finalize Strategic Agreement to Deliver Breakthrough Dry Eye Treatments and Aesthetic Procedures to Eyecare Physicians Nationwide
KNOXVILLE, Tenn., May 31, 2025 /PRNewswire/ -- Novoxel Inc. and GPOphtho announce their agreement to expand access to Novoxel's innovative Tixel® device family across the United States. This collaboration aims to deliver breakthrough dry eye treatments and aesthetic procedures to eyecare physicians nationwide. Expanding Access to Advanced Dry Eye and Aesthetic Solutions The agreement grants GPOphtho's network of ophthalmologists and optometrists discounted pricing and value-added packages for Novoxel's Tixel devices. Tixel i® is specifically designed to treat Meibomian Gland Dysfunction (MGD), offering a fast and targeted solution for both upper and lower eyelids. A recent clinical trial (Sanni, et al, 2025) concluded that Tixel i is a safe, non-pharmacologic, first-line treatment for MGD. "What sets Tixel i apart from other dry eye treatments is that it only takes 2 minutes for both eyes to be treated. Unlike older technology, Tixel i safely treats upper and lower eyelids to maximize improvement," says Cynthia Matossian, MD, FACS, and CEO of GPOphtho. The FDA-cleared family of products provide year-round treatments for all skin types and age groups. They offer non-invasive rejuvenation without needles, bleeding, or pain, minimal downtime, no expensive consumables, and are radiation-free. Empowering Eyecare Physicians with New Revenue Streams "Eyecare physicians are uniquely positioned to incorporate aesthetic procedures into their practices due to their expertise in the periocular anatomy and their familiarity with ophthalmic laser technology," says Cynthia Matossian, MD, FACS, and CEO of GPOphtho. This agreement will enable eyecare professionals to easily integrate both functional and cosmetic procedures, creating new revenue streams and enhancing patient satisfaction. Both Novoxel and GPOphtho are committed to bringing innovative, cutting-edge technology to more patients and practices across the US. For product demos or pricing information, visit Existing GPOphtho members can inquire about adding Tixel through their GPOphtho contact. ABOUT NOVOXELEstablished in 2011, Novoxel Ltd. focuses on scientific and clinical innovation. Novoxel has been granted numerous patents around the world. The company's Tixel family of products use proprietary Thermo-Mechanical Action (TMA®) to deliver noticeable clinical results even though treatments are non-invasive. There is minimal downtime, no expensive single-use cartridges, no bleeding, and minimal/no pain. Because the affordable treatments are radiation-free, safety eyewear is not required for clinicians. Visit for more information. ABOUT GPOPHTHOGPOphtho's mission is to save our members time and money for all of their business needs by becoming the most comprehensive ophthalmic group purchasing organization. By leveraging collective buying power, GPOphtho is able to negotiate discounted rates and value-added packages for a diverse range of products and services, allowing physicians and their staff to focus on providing the best care for their patients. Plus, members can take advantage of all GPOphtho's negotiated contracts without paying administrative fees. For more information, visit Interested eyecare physicians can join GPOphtho at no cost. View original content to download multimedia: SOURCE Novoxel Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
WebMD
4 days ago
- Business
- WebMD
FDA Approves New Treatment for Dry Eye Disease
May 30, 2025 -- The FDA has approved a new treatment for dry eye disease (DED) after studies showed it can help stimulate natural tear production as early as the first day of use. The new drug, known as acoltremon but sold as Tryptyr, is the first of its kind that offers hope to about 38 million people in the U.S. living with DED, fewer than 10% of whom currently use prescription treatments. DED is a condition where the eyes don't make enough tears or when tears dry up too quickly. It can cause burning, itching, light sensitivity, blurry vision, and a gritty or sandy feeling. Once thought to mostly affect older adults, it can affect all age groups, often due to long screen times. Many treatments are slow to work or hard to use, highlighting the need for better options that treat the root cause, not just the symptoms. Alcon, the maker of Tryptyr, says the FDA approved the drug based on two late-stage trials with about 930 people who have dry eye disease. Participants got either Tryptyr or a placebo. By day 14, up to four times more people using Tryptyr boosted their tear production. In the two trials, 42.6% and 53.2% of Tryptyr users improved, compared to just 8.2% and 14.4% of placebo users. The drug also started relieving symptoms as early as day one, with effects lasting through day 90. Tryptyr works by targeting TRPM8 proteins that activate nerves in the eye to boost tear production. It comes in single-use vials, with one drop needed in each eye twice a day. Alcon plans to launch it in the U.S. in the third quarter of 2025. Marjan Farid, MD, professor of ophthalmology at the University of California, Irvine, said the new treatment option might overcome the current challenges for patients. 'Tryptyr is the first eye drop that stimulates corneal nerves to directly address tear deficiency, a known cause of dry eye disease,' she said in a statement.
